Phase II Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01687673|
Recruitment Status : Active, not recruiting
First Posted : September 19, 2012
Last Update Posted : June 21, 2017
|Condition or disease||Intervention/treatment||Phase|
|Hepatocellular Carcinoma||Drug: Temsirolimus Drug: Sorafenib:||Phase 2|
The hypothesis of this single-arm phase II study is that the combination of temsirolimus and sorafenib will achieve a clinically-meaningful median time to progression (TTP) of at least 6 months, with null hypothesis of less than or equal to 3 months, in first-line systemic therapy for patients with advanced HCC. A randomized trial would be required to formally compare the efficacy of this combination to sorafenib alone and will be indicated if this phase II study achieves a median TTP of at least 6 months. An interim safety analysis will employ stopping rules after 30% of planned patients have been treated with at least one dose of protocol therapy to ensure the combination does not confer excessive toxicity.
A key aspect of this study will be the requirement of histologic confirmation along with adequate archival tissue for correlative tissue analyses to explore new biomarkers of response to mTOR inhibition. Circulating biomarker data including enumeration of circulating tumor cells (CTC) and measurement of the tumor marker AFP will be performed at specific timepoints to evaluate for predictive value. Specimen banking of tissue, serum, and peripheral blood mononuclear cells will be undertaken to enable future novel biomarker studies. Modified RECIST will be performed in addition to standard RECIST 1.1 to explore for improved imaging predictors of response.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||27 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase II Trial of the Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma|
|Actual Study Start Date :||October 5, 2012|
|Actual Primary Completion Date :||May 27, 2016|
|Estimated Study Completion Date :||September 2017|
Combination temsirolimus plus sorafenib
10 mg weekly will be administered intravenously over 30 to 60 minutes using an infusion pump starting on Cycle 1, Day 1 of study enrollment.Drug: Sorafenib:
200 mg tablet twice daily starting on Cycle 1, Day 1 of study enrollment after completion of temsirolimus infusion.
- Median time to progression (TTP) [ Time Frame: 24 months ]Median TTP will be calculated in months from date of first dose of protocol therapy to date of removal from study for progression; Kaplan-Meier methods will be used to summarize the primary endpoint (median TTP).
- Response rate (RR) [ Time Frame: 24 months ]Response rate (RR) will be measured by RECIST version 1.1; measurements will be presented descriptively for the study cohort.
- Progression free survival (PFS) [ Time Frame: 24 months ]Median PFS will be calculated in months from date of first dose of protocol therapy to date of documented disease progression or death from any cause. Kaplan-Meier methods will be used to summarize time-to-event outcomes including the primary endpoint (median TTP) and secondary endpoints (PFS, TTF, OS).
- Overall survival (OS) [ Time Frame: 24 months ]Median OS for all enrolled patients (intention-to-treat) will be calculated from date of first dose of protocol therapy until date of death, using chart review and/or follow up phone calls to determine date of death in patients after removal from study.
- Time to treatment failure (TTF) [ Time Frame: 24 months ]TTF will be measured from date of first dose of protocol therapy to date of study discontinuation for progression, death, or toxicity.
- Toxicity & tolerability [ Time Frame: 24 months ]In patients with baseline AFP ≥ 20 ng/mL, AFP response will be measured by the percent change from baseline value to the value at the time of best AFP response. The change in AFP will also be examined for association with absolute TTP and best response.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01687673
|United States, California|
|University of California, San Francisco|
|San Francisco, California, United States, 94143|
|United States, Illinois|
|Robert H Lurie Comprehensive Cancer Center|
|Chicago, Illinois, United States, 60611|
|Study Chair:||Kate Kelley, MD||University of California, San Francisco|
|Principal Investigator:||Kate Kelley, MD||University of California, San Francisco|